Cerebellar degeneration-related autoantigen 1 (CDR1) gene expression in prostate cancer cell lines

International Journal of Biological Markers

Volumn 29, Issue 3, 2014, Pages e288-e290

  Salemi, Michele ^b   Fraggetta, Filippo ^c   Galia, Antonio ^c   Pepe, Pietro ^c   Cimino, Laura ^a   Condorelli, Rosita A ^a   Calogero, Aldo E ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

Author keywords

CDR1 gene; mRNA; Prostate cancer; qRT PCR

Indexed keywords

ANDROGEN RECEPTOR; AUTOANTIGEN; CEREBELLAR DEGENERATION RELATED AUTOANTIGEN 1; UNCLASSIFIED DRUG; CDR1 PROTEIN, HUMAN; DNA; MESSENGER RNA; NERVE PROTEIN; TUMOR MARKER;

ARTICLE; CONTROLLED STUDY; GENE MAPPING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MRNA EXPRESSION ASSAY; NEUROBLASTOMA; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

AUTOANTIGENS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NERVE TISSUE PROTEINS; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 84907479271     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000062     Document Type: Article

References (18)

1. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990; 17(4): 337-347.
2. Kucuk O. Chemoprevention of prostate cancer. Cancer Metastasis Rev. 2002; 21(2): 111-124.
3. Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ. 1998; 159(7): 807-813.
4. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2001; 93(5): 388-395.
5. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003; 53(1): 5-26.
6. Trojan L, Kiknavelidze K, Knoll T, Alken P, Michel MS. Prostate cancer therapy: standard management, new options and experimental approaches. Anticancer Res. 2005; 25(1B): 551-561.
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1): 43-66.
8. Dropcho EJ, Chen YT, Posner JB, Old LJ. Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci USA. 1987; 84(13): 4552-4556.
9. Avancès C, Georget V, Térouanne B, et al. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens. Mol Cell Endocrinol. 2001; 184(1-2): 13-24.
10. Cussenot O, Berthon P, Cochand-Priollet B, Maitland NJ, Le Duc A. Immunocytochemical comparison of cultured normal epithelial prostatic cells with prostatic tissue sections. Exp Cell Res. 1997; 214(1): 83-92.
11. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res. 1983; 43(4): 1809-1818.
12. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17: 16-23.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods. 2001; 25(4): 402-408.
14. Chen YT, Rettig WJ, Yenamandra AK, et al. Cerebellar degeneration- related antigen: a highly conserved neuroectodermal marker mapped to chromosomes X in human and mouse. Proc Natl Acad Sci USA. 1990; 87(8): 3077-3081.
15. Kouprina N, Lee NC, Pavlicek A, et al. Exclusion of the 750-kb genetically unstable region at Xq27 as a candidate locus for prostate malignancy in HPCX1-linked families. Genes Chromosomes Cancer. 2012; 51(10): 933-948.
16. Varghese JS, Easton DF. Genome-wide association studies in common cancers—what have we learnt? Curr Opin Genet Dev. 2010; 20(3): 201-209.
17. Colloca G, Venturino A. The evolving role of familial history for prostate cancer. Acta Oncol. 2011; 50(1): 14-24.
18. Xu J, Gillanders EM, Isaacs SD, et al. Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. Prostate. 2003; 57(4): 320-325.